Taysha Gene Therapies, Inc. reported $5.5M of revenue over the trailing twelve months, −32% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $5.5M (to Q2 2026). Net income: −$150M, trailing twelve months to Q2 2026. Free cash flow: −$133M, trailing twelve months to Q2 2026. EPS: −$0.42, trailing twelve months to Q2 2026.

TSHATaysha Gene Therapies, Inc.

Healthcare

$4.49+59% 1Y

$4.49

$2.8752 weeks$6.98

TSHA as reported

Taysha Gene Therapies, Inc. reported $5.5M of revenue over the trailing twelve months, −32% on the year before. 9 reported series are charted on this page, each one as filed.

$5.5M

Revenue, trailing twelve months · to Q2 2026 · −32% against the twelve months before

Net income: −$150M
Net income · +61% year on year · trailing twelve months to Q2 2026
Free cash flow: −$133M
Free cash flow · +61% year on year · trailing twelve months to Q2 2026
EPS: −$0.42
EPS · +24% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TSHA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$5.5M	−32%	Q2 2026
Net income	−$150M	+61%	Q2 2026
EPS	−$0.42	+24%	Q2 2026
Operating margin	−1178%	n/a	Q2 2025 · 4 quarters behind
Net margin	−1161%	n/a	Q2 2025 · 4 quarters behind
ROE	−47%	n/a	Q2 2026
ROA	−35%	n/a	Q2 2026
ROIC	497%	n/a	Q2 2026
Free cash flow	−$133M	+61%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.